Abstracts tagged "Health Services Research"

Abstract Number: 1177 • ACR Convergence 2024
Supporting Implementation of Group Physical Therapy for Knee Osteoarthritis: Results of a Multisite Implementation Trial
Kelli Allen¹, Sara Webb², Livia Anderson², lauren Abbate³, Lindsay Ballengee⁴, Cynthia Coffman², Connor Drake⁵, Graham Cummin⁵, Helen Hoenig⁵, Jaime Hughes⁶, Nina Sperber⁵, Matthew Tucker⁵, Amy Webster⁵, Leah Zullig⁵, Courtney Van Houtven⁵ and Susan Hastings⁵, ¹University of North Carolina, Durham, NC, ²Durham VA Healthcare System, Durham, NC, ³VA Eastern Colorado, Denver, CO, ⁴Duke University, Durham, NC, ⁵Durham VA Healthcare System, Durham, ⁶Wake Forest University, Winston Salem
Background/Purpose: Prior research has shown that compared to individual PT, group-based physical therapy (Group PT) yields equivalent or greater improvement in outcomes for patients with…
Abstract Number: 1896 • ACR Convergence 2024
The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
Priyanka Chandratre¹, Joht Chandan², Ben Hammond³, Rasiah Thayakaran³, Samuel Cusworth³, Nicola Adderley³ and Deva Situnayake⁴, ¹The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, ²Institute of Applied Health Research, Birmingham, United Kingdom, ³Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ⁴Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom
Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
Abstract Number: 0199 • ACR Convergence 2024
Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Mangala Rajan², Orysya Soroka², Karen Onel³, Monika Safford² and Iris Navarro Millan⁴, ¹Weill Cornell Medicine/ Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: 50-80% of children with childhood-onset systemic lupus erythematosus (cSLE) develop lupus nephritis (LN). Children from historically marginalized communities are disproportionately affected by cSLE and…
Abstract Number: 1016 • ACR Convergence 2024
Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S
Ashkan Ara¹, Matthew Chenoweth², Srikanth Kadiyala², Utibe Essien³ and Christopher Scannell³, ¹Division of Rheumatology, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, ²Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, ³Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles
Background/Purpose: Long-term management of rheumatoid arthritis (RA) relies on disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic (tsDMARDs). About 40%…
Abstract Number: 1239 • ACR Convergence 2024
Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients
Vanessa Bartsch¹, Basel Habboub², Kathrin Standfest¹, Johannes Knitza³, Georg Schett⁴ and Axel Hueber², ¹Division Rheumatology, Klinikum Nuernberg, Nuernberg, Germany, ²Klinikum Nuernberg, Nuernberg, Germany, ³Institute for Digital Medicine, Philipps-University Marburg and University Hospital of Giessen and Marburg, Marburg, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at higher risk for malignancies and infections. Effective management strategies for these comorbidities are urgently needed. We…
Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
Abstract Number: 0171 • ACR Convergence 2023
A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews
Vibeke Strand¹, Prajakta Masurkar², Jennifer Reckleff³, Taylor Schwartz⁴, Alison Silverstein⁴, Jennifer Osborne⁴, Josie Lloyd⁴, Brian Leinwand⁴, Elaine Karis⁵, Fatima Barbar-Smiley⁶ and Karen Costenbader⁷, ¹Stanford University, Portola Valley, CA, ²Amgen, Inc., Atlanta, GA, ³Amgen, Inc., Westlake Village, CA, ⁴Inovalon Insights, Bowie, MD, ⁵Amgen, Inc., Colts Neck, NJ, ⁶Amgen, Inc., Dublin, OH, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
Abstract Number: 0997 • ACR Convergence 2023
Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus
W. Cliff Rutter, Jean Park, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) have higher rates of psychiatric comorbidities, particularly depression and anxiety. Comorbid…
Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
Abstract Number: 2002 • ACR Convergence 2023
Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Yamei Wang⁴, Leny Pearman⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Boston, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…
Abstract Number: 0172 • ACR Convergence 2023
Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review
Krystel Aouad¹, Maarten de Wit², Muriel Elhai³, Diego Benavent⁴, Heidi Bertheussen⁵, Jette Primdahl⁶, Codruta Zabalan⁷, Paul Studenic⁸ and Laure Gossec⁹, ¹Saint George Hospital University Medical Center, Beirut, Lebanon, ²Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ³University Hospital zurich, University of Zurich, Zurich, Switzerland, ⁴Hospital la Paz, Madrid, Spain, ⁵Patient Research Partner, Oslo, Norway, ⁶University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ⁷Patient Research Partner, Romania, Romania, Romania, ⁸Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Patient research partners (PRPs) participate in research teams and provide unique and valuable input. Their integration as equal partners is recommended (1). However, PRP…
Abstract Number: 0998 • ACR Convergence 2023
Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives
Rebecca Slotkin¹, Daniel Granda Calderón², Joselito Malca Hernandez², Diego Cabrera³, Carlos Manuel Benites Villafane⁴, Patricia Jannet García⁵ and Evelyn Hsieh⁶, ¹Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health, New Haven, CT, ²Facultad de Medicina Alberto Hurtado de la Universidad Peruana Cayetano Heredia, Lima, Peru, ³Yale University, Department of Medicine, Section of Rheumatology; Department of Internal Medicine, Waterbury Hospital, New Haven, CT, ⁴Ministerio de Salud, Peru, Lima, Peru, ⁵Epidemiology, STD, and HIV Unit, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru, ⁶Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT
Background/Purpose: Persons living with HIV (PLWH) have a higher risk of developing age-related non-communicable diseases (NCDs), such as osteoporosis and sarcopenia. In Peru, HIV providers…
Abstract Number: 1656 • ACR Convergence 2023
Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)
anna Fryxelius¹, Amy Martinsen², Ida Løchting³, Linda Aimee Hartford Kvæl⁴, Astrid Lunestad², Astrid Bergland⁴ and Kjersti Storheim², ¹Norwegian Rheumatism Association / REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ⁴OsloMET, Oslo, Norway
Background/Purpose: Patient and public involvement (PPI) is gaining increasing recognition as important to ensure research is relevant and to reduce avoidable research waste. Active collaboration…
Abstract Number: 2023 • ACR Convergence 2023
Transition Readiness over Time in a Rheumatology Transition Clinic
Background/Purpose: In 2018 we designed a Rheumatology Transition clinic to care for adolescent patients with autoimmune disease. We incorporate Health Care Transition curriculum (HCT) into…
Abstract Number: 0174 • ACR Convergence 2023
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Healthcare utilization is increasing among patients with rheumatic diseases. While several studies have assessed healthcare utilization in rheumatoid arthritis (RA) patients, few studies have…

« Previous Page
1
…
3
4
5
6
7
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].